Skip to main content
SpringerLink
Log in
Book cover

Treatment and Prevention of Malaria pp 95–111Cite as

Other 4-Methanolquinolines, Amyl Alcohols and Phentathrenes: Mefloquine, Lumefantrine and Halofantrine

  • Chapter
  • First Online:

Part of the book series: Milestones in Drug Therapy ((MDT))

Abstract

This chapter describes mefloquine, pyronaridine, halofantrine, piperaquine and lumefantrine under the broader title of the 4-methanolquinolines, amyl alcohols and phentathrenes. We provide a brief resume of each drug, in terms of their chemical properties, formulae, pharmacokinetics, clinical indications for use, and their efficacy and safety. Recognizing the limited number of antimalarials available, and in the developmental pipeline, attention is focussed on describing the history of each drug and how their indications have evolved as data on safety in human populations accumulates over time, and how patterns of use have changed with growing multiple drug resistance. Their combined use with the artemisinin derivatives is briefly described and readers are recommended to consult other chapters in this book which more fully describe such combinations.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Olliaro P (2001) Mode of action and mechanisms of resistance for antimalarial drugs. Pharmacol Ther 89:207–219

    Article  PubMed  CAS  Google Scholar 

  2. Hoppe HC, van Schalkwyk DA, Wiehart UI, Meredith SA, Egan J, Weber BW (2004) Antimalarial quinolines and artemisinin inhibit endocytosis in Plasmodium falciparum. Antimicrob Agents Chemother 48:2370–2378

    Article  PubMed  CAS  Google Scholar 

  3. Sweeney TR (1981) The present status of malaria chemotherapy: mefloquine, a novel antimalarial. Med Res Rev 1:281–301

    Article  PubMed  CAS  Google Scholar 

  4. Karle JM, Olmeda R, Gerena L, Milhous WK (1993) Plasmodium falciparum: role of absolute stereochemistry in the antimalarial activity of synthetic amino alcohol antimalarial agents. Exp Parasitol 76:345–351

    Article  PubMed  CAS  Google Scholar 

  5. Brocks DR, Mehvar R (2003) Stereoselectivity in the pharmacodynamics and pharmacokinetics of the chiral antimalarial drugs. Clin Pharmacokinet 42:1359–1382

    Article  PubMed  CAS  Google Scholar 

  6. Simpson JA, Price R, ter Kuile F, Teja-Isavatharm P, Nosten F, Chongsuphajaisiddhi T, Looareesuwan S, Aarons L, White NJ (1999) Population pharmacokinetics of mefloquine in patients with acute falciparum malaria. Clin Pharmacol Ther 66:472–484

    Article  PubMed  CAS  Google Scholar 

  7. Gimenez F, Pennie RA, Koren G, Crevoisier C, Wainer IW, Farinotti R (1994) Stereoselective pharmacokinetics of mefloquine in healthy Caucasians after multiple doses. J Pharm Sci 83:824–827

    Article  PubMed  CAS  Google Scholar 

  8. Martin C, Gimenez F, Bangchang KN, Karbwang J, Wainer IW, Farinotti R (1994) Whole blood concentrations of mefloquine enantiomers in healthy Thai volunteers. Eur J Clin Pharmacol 47:85–87

    Article  PubMed  CAS  Google Scholar 

  9. Hellgren U, Jastrebova J, Jerling M, Krysen B, Bergqvist Y (1996) Comparison between concentrations of racemic mefloquine, its separate enantiomers and the carboxylic acid metabolite in whole blood serum and plasma. Eur J Clin Pharmacol 51:171–173

    Article  PubMed  CAS  Google Scholar 

  10. Bourahla A, Martin C, Gimenez F, Singhasivanon V, Attanath P, Sabchearon A, Chongsuphajaisiddhi T, Farinotti R (1996) Stereoselective pharmacokinetics of mefloquine in young children. Eur J Clin Pharmacol 50:241–244

    Article  PubMed  CAS  Google Scholar 

  11. Kerb R, Fux R, Morike K, Kremsner PG, Gil JP, Gleiter CH, Schwab M (2009) Pharmacogenetics of antimalarial drugs: effect on metabolism and transport. Lancet Infect Dis 9:760–774

    Article  PubMed  CAS  Google Scholar 

  12. Svensson US, Alin H, Karlsson MO, Bergqvist Y, Ashton M (2002) Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria. Eur J Clin Pharmacol 58:339–351

    Article  PubMed  CAS  Google Scholar 

  13. Phillips-Howard PA, Steffen R, Kerr L, Vanhauwere B, Schildknecht J, Fuchs E, Edwards R (1998) Safety of mefloquine and other antimalarial agents in the first trimester of pregnancy. J Travel Med 5:121–126

    Article  PubMed  CAS  Google Scholar 

  14. Nosten F, Vincenti M, Simpson J, Yei P, Thwai KL, de Vries A, Chongsuphajaisiddhi T, White NJ (1999) The effects of mefloquine treatment in pregnancy. Clin Infect Dis 28:808–815

    Article  PubMed  CAS  Google Scholar 

  15. Steketee RW, Wirima JJ, Slutsker L, Roberts JM, Khoromana CO, Heymann DL, Breman JG (1996) Malaria parasite infection during pregnancy and at delivery in mother, placenta, and newborn: efficacy of chloroquine and mefloquine in rural Malawi. Am J Trop Med Hyg 55(1 Suppl):24–32

    PubMed  CAS  Google Scholar 

  16. Gosling RD, Gesase S, Mosha JF, Carneiro I, Hashim R, Lemnge M, Mosha FW, Greenwood B, Chandramohan D (2009) Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial. Lancet 374:1521–1532

    Article  PubMed  CAS  Google Scholar 

  17. Briand V, Bottero J, Noel H, Masse V, Cordel H, Guerra J, Kossou H, Fayomi B, Ayemonna P, Fievet N et al (2009) Intermittent treatment for the prevention of malaria during pregnancy in Benin: a randomized, open-label equivalence trial comparing sulfadoxine-pyrimethamine with mefloquine. J Infect Dis 200:991–1001

    Article  PubMed  CAS  Google Scholar 

  18. Nosten F, ter Kuile F, Chongsuphajaisiddhi T, Luxemburger C, Webster HK, Edstein M, Phaipun L, Thew KL, White NJ (1991) Mefloquine-resistant falciparum malaria on the Thai-Burmese border. Lancet 337:1140–1143

    Article  PubMed  CAS  Google Scholar 

  19. Nosten F, Price RN (1995) New antimalarials. A risk-benefit analysis. Drug Saf 12:264–273

    Article  PubMed  CAS  Google Scholar 

  20. White NJ (1992) Antimalarial drug resistance: the pace quickens. J Antimicrob Chemother 30:571–585

    Article  PubMed  CAS  Google Scholar 

  21. ter Kuile FO, Nosten F, Thieren M, Luxemburger C, Edstein MD, Chongsuphajaisiddhi T, Phaipun L, Webster HK, White NJ (1992) High-dose mefloquine in the treatment of multidrug-resistant falciparum malaria. J Infect Dis 166:1393–1400

    Article  PubMed  Google Scholar 

  22. Fontanet AL, Johnston DB, Walker AM, Rooney W, Thimasarn K, Sturchler D, Macdonald M, Hours M, Wirth DF (1993) High prevalence of mefloquine-resistant falciparum malaria in eastern Thailand. Bull World Health Organ 71:377–383

    PubMed  CAS  Google Scholar 

  23. Fontanet AL, Johnston BD, Walker AM, Bergqvist Y, Hellgren U, Rooney W (1994) Falciparum malaria in eastern Thailand: a randomized trial of the efficacy of a single dose of mefloquine. Bull World Health Organ 72:73–78

    PubMed  CAS  Google Scholar 

  24. ter Kuile FO, Nosten F, Luxemburger C, Kyle D, Teja-Isavatharm P, Phaipun L, Price R, Chongsuphajaisiddhi T, White NJ (1995) Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3673 patients. Bull World Health Organ 73:631–642

    PubMed  Google Scholar 

  25. Ter Kuile FO, Teja-Isavatharm P, Edstein MD, Keeratithakul D, Dolan G, Nosten F, Phaipun L, Webster HK, White NJ (1994) Comparison of capillary whole blood, venous whole blood, and plasma concentrations of mefloquine, halofantrine, and desbutyl-halofantrine measured by high-performance liquid chromatography. Am J Trop Med Hyg 51:778–784

    PubMed  Google Scholar 

  26. Nosten F, van Vugt M, Price R, Luxemburger C, Thway KL, Brockman A, McGready R, ter Kuile F, Looareesuwan S, White NJ (2000) Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 356:297–302

    Article  PubMed  CAS  Google Scholar 

  27. Carrara VI, Sirilak S, Thonglairuam J, Rojanawatsirivet C, Proux S, Gilbos V, Brockman A, Ashley EA, McGready R, Krudsood S et al (2006) Deployment of early diagnosis and mefloquine-artesunate treatment of falciparum malaria in Thailand: the Tak Malaria Initiative. PLoS Med 3:e183

    Article  PubMed  Google Scholar 

  28. Carrara VI, Zwang J, Ashley EA, Price RN, Stepniewska K, Barends M, Brockman A, Anderson T, McGready R, Phaiphun L et al (2009) Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One 4:e4551

    Article  PubMed  Google Scholar 

  29. Price R, Robinson G, Brockman A, Cowman A, Krishna S (1997) Assessment of pfmdr 1 gene copy number by tandem competitive polymerase chain reaction. Mol Biochem Parasitol 85:161–169

    Article  PubMed  CAS  Google Scholar 

  30. Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, Phaipun L, Patel R, Laing K, Looareesuwan S, White NJ et al (2004) Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 364:438–447

    Article  PubMed  CAS  Google Scholar 

  31. Simpson JA, Watkins ER, Price RN, Aarons L, Kyle DE, White NJ (2000) Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. Antimicrob Agents Chemother 44:3414–3424

    Article  PubMed  CAS  Google Scholar 

  32. Palmer KJ, Holliday SM, Brogden RN (1993) Mefloquine: a review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 45:430–475

    Article  PubMed  CAS  Google Scholar 

  33. Ashley EA, McGready R, Hutagalung R, Phaiphun L, Slight T, Proux S, Thwai KL, Barends M, Looareesuwan S, White NJ et al (2005) A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Clin Infect Dis 41:425–432

    Article  PubMed  CAS  Google Scholar 

  34. Bem JL, Kerr L, Stuerchler D (1992) Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions. J Trop Med Hyg 95:167–179

    PubMed  CAS  Google Scholar 

  35. Phillips-Howard PA, ter Kuile FO (1995) CNS adverse events associated with antimalarial agents. Fact or fiction? Drug Saf 12:370–383

    Article  PubMed  CAS  Google Scholar 

  36. WHO (1991) Review of central nervous system adverse events related to the antimalarial drug, mefloquine (1985–1990). World Health Organization, Geneva

    Google Scholar 

  37. Schlagenhauf P, Steffen R, Lobel H, Johnson R, Letz R, Tschopp A, Vranjes N, Bergqvist Y, Ericsson O, Hellgren U et al (1996) Mefloquine tolerability during chemoprophylaxis: focus on adverse event assessments, stereochemistry and compliance. Trop Med Int Health 1:485–494

    Article  PubMed  CAS  Google Scholar 

  38. Roche Laboratories Inc (2008) Lariam® (mefloquine hydrochloride) Complete Product Information. US Package Insert, Nutley, NJ

    Google Scholar 

  39. Nevin RL, Pietrusiak PP, Caci JB (2008) Prevalence of contraindications to mefloquine use among USA military personnel deployed to Afghanistan. Malar J 7:30

    Article  PubMed  Google Scholar 

  40. Hill DR (1991) Pre-travel health, immunization status, and demographics of travel to the developing world for individuals visiting a travel medicine service. Am J Trop Med Hyg 45:263–270

    PubMed  CAS  Google Scholar 

  41. Nevin RL (2009) Epileptogenic potential of mefloquine chemoprophylaxis: a pathogenic hypothesis. Malar J 8:188

    Article  PubMed  Google Scholar 

  42. Taylor WR, White NJ (2004) Antimalarial drug toxicity: a review. Drug Saf 27:25–61

    Article  PubMed  CAS  Google Scholar 

  43. Baird JK (2005) Effectiveness of antimalarial drugs. N Engl J Med 352:1565–1577

    Article  PubMed  CAS  Google Scholar 

  44. Weinke T, Trautmann M, Held T, Weber G, Eichenlaub D, Fleischer K, Kern W, Pohle HD (1991) Neuropsychiatric side effects after the use of mefloquine. Am J Trop Med Hyg 45:86–91

    PubMed  CAS  Google Scholar 

  45. Luxemburger C, Nosten F, ter Kuiile F, Frejacques L, Chongsuphajaisiddhi T, White NJ (1991) Mefloquine for multidrug-resistant malaria. Lancet 338:1268

    Article  PubMed  CAS  Google Scholar 

  46. Nguyen TH, Day NP, Ly VC, Waller D, Mai NT, Bethell DB, Tran TH, White NJ (1996) Post-malaria neurological syndrome. Lancet 348:917–921

    Article  PubMed  CAS  Google Scholar 

  47. Pham YT, Nosten F, Farinotti R, White NJ, Gimenez F (1999) Cerebral uptake of mefloquine enantiomers in fatal cerebral malaria. Int J Clin Pharmacol Ther 37:58–61

    PubMed  CAS  Google Scholar 

  48. Gimenez F, Gillotin C, Basco LK, Bouchaud O, Aubry AF, Wainer IW, Le Bras J, Farinotti R (1994) Plasma concentrations of the enantiomers of halofantrine and its main metabolite in malaria patients. Eur J Clin Pharmacol 46:561–562

    Article  PubMed  CAS  Google Scholar 

  49. Pham YT, Regina A, Farinotti R, Couraud P, Wainer IW, Roux F, Gimenez F (2000) Interactions of racemic mefloquine and its enantiomers with P-glycoprotein in an immortalised rat brain capillary endothelial cell line, GPNT. Biochim Biophys Acta 1524:212–219

    Article  PubMed  CAS  Google Scholar 

  50. Toovey S (2009) Mefloquine neurotoxicity: a literature review. Travel Med Infect Dis 7:2–6

    Article  PubMed  Google Scholar 

  51. Milner E, McCalmont W, Bhonsle J, Caridha D, Carroll D, Gardner S, Gerena L, Gettayacamin M, Lanteri C, Luong T et al (2010) Structure-activity relationships amongst 4-position quinoline methanol antimalarials that inhibit the growth of drug sensitive and resistant strains of Plasmodium falciparum. Bioorg Med Chem Lett 20:1347–1351

    Article  PubMed  CAS  Google Scholar 

  52. Milner E, McCalmont W, Bhonsle J, Caridha D, Cobar J, Gardner S, Gerena L, Goodine D, Lanteri C, Melendez V et al (2010) Anti-malarial activity of a non-piperidine library of next-generation quinoline methanols. Malar J 9:51

    Article  PubMed  Google Scholar 

  53. Weiss SM, Benwell K, Cliffe IA, Gillespie RJ, Knight AR, Lerpiniere J, Misra A, Pratt RM, Revell D, Upton R et al (2003) Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson’s disease. Neurology 61:S101–S106

    Article  PubMed  CAS  Google Scholar 

  54. Gillespie RJ, Adams DR, Bebbington D, Benwell K, Cliffe IA, Dawson CE, Dourish CT, Fletcher A, Gaur S, Giles PR et al (2008) Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives. Bioorg Med Chem Lett 18:2916–2919

    Article  PubMed  CAS  Google Scholar 

  55. Gofton TE, Al-Khotani A, O’Farrell B, Ang LC, McLachlan RS (2011) Mefloquine in the treatment of progressive multifocal leukoencephalopathy. J Neurol Neurosurg Psychiatry 82:452–455

    Article  PubMed  CAS  Google Scholar 

  56. Brickelmaier M, Lugovskoy A, Kartikeyan R, Reviriego-Mendoza MM, Allaire N, Simon K, Frisque RJ, Gorelik L (2009) Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother 53:1840–1849

    Article  PubMed  CAS  Google Scholar 

  57. Keiser J, Utzinger J (2010) The drugs we have and the drugs we need against major helminth infections. Adv Parasitol 73:197–230

    Article  PubMed  Google Scholar 

  58. Holtfreter MC, Loebermann M, Klammt S, Sombetzki M, Bodammer P, Riebold D, Kinzelbach R, Reisinger EC (2011) Schistosoma mansoni: schistosomicidal effect of mefloquine and primaquine in vitro. Exp Parasitol 127:270–276

    Article  PubMed  CAS  Google Scholar 

  59. Xiao SH, Xue J, Li-Li X, Zhang YN, Qiang HQ (2010) Effectiveness of mefloquine against Clonorchis sinensis in rats and Paragonimus westermani in dogs. Parasitol Res 107:1391–1397

    Article  PubMed  Google Scholar 

  60. Auparakkitanon S, Chapoomram S, Kuaha K, Chirachariyavej T, Wilairat P (2006) Targeting of hematin by the antimalarial pyronaridine. Antimicrob Agents Chemother 50:2197–2200

    Article  PubMed  CAS  Google Scholar 

  61. Chavalitshewinkoon-Petmitr P, Pongvilairat G, Auparakkitanon S, Wilairat P (2000) Gametocytocidal activity of pyronaridine and DNA topoisomerase II inhibitors against multidrug-resistant Plasmodium falciparum in vitro. Parasitol Int 48:275–280

    Article  PubMed  CAS  Google Scholar 

  62. Tshefu AK, Gaye O, Kayentao K, Thompson R, Bhatt KM, Sesay SS, Bustos DG, Tjitra E, Bedu-Addo G, Borghini-Fuhrer I et al (2010) Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet 375:1457–1467

    Article  PubMed  CAS  Google Scholar 

  63. Park SH, Pradeep K (2010) Absorption, distribution, excretion, and pharmacokinetics of 14 C-pyronaridine tetraphosphate in male and female Sprague-Dawley rats. J Biomed Biotechnol 2010:590707

    PubMed  Google Scholar 

  64. Wattanavijitkul T. (2010) Population pharmacokinetics of pyronaridine in the treatment of malaria. Ph.D. dissertation, University of Iowa. http://ir.uiowa.edu/etd/622. Accessed 15 Apr 2011

  65. Looareesuwan S, Kyle DE, Viravan C, Vanijanonta S, Wilairatana P, Wernsdorfer WH (1996) Clinical study of pyronaridine for the treatment of acute uncomplicated falciparum malaria in Thailand. Am J Trop Med Hyg 54:205–209

    PubMed  CAS  Google Scholar 

  66. Elueze EI, Croft SL, Warhurst DC (1996) Activity of pyronaridine and mepacrine against twelve strains of Plasmodium falciparum in vitro. J Antimicrob Chemother 37:511–518

    Article  PubMed  CAS  Google Scholar 

  67. de Villiers KA, Marques HM, Egan TJ (2008) The crystal structure of halofantrine-ferriprotoporphyrin IX and the mechanism of action of arylmethanol antimalarials. J Inorg Biochem 102:1660–1667

    Article  PubMed  Google Scholar 

  68. Sanchez CP, Rotmann A, Stein WD, Lanzer M (2008) Polymorphisms within PfMDR1 alter the substrate specificity for anti-malarial drugs in Plasmodium falciparum. Mol Microbiol 70:786–798

    PubMed  CAS  Google Scholar 

  69. ter Kuile FO, Dolan G, Nosten F, Edstein MD, Luxemburger C, Phaipun L, Chongsuphajaisiddhi T, Webster HK, White NJ (1993) Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria [see comments]. Lancet 341:1044–1049

    Article  PubMed  Google Scholar 

  70. Nosten F, ter Kuile F, Luxemburger C, Woodrow C, Kyle DE, Chongsuphajaisiddhi T, White NJ (1993) Cardiac effects of antimalarial treatment with halofantrine. Lancet 341:1054–1056

    Article  PubMed  CAS  Google Scholar 

  71. Ashley EA, Stepniewska K, Lindegardh N, Annerberg A, Kham A, Brockman A, Singhasivanon P, White NJ, Nosten F (2007) How much fat is necessary to optimize lumefantrine oral bioavailability? Trop Med Int Health 12:195–200

    Article  PubMed  CAS  Google Scholar 

  72. Tie H, Walker BD, Singleton CB, Valenzuela SM, Bursill JA, Wyse KR, Breit SN, Campbell TJ (2000) Inhibition of HERG potassium channels by the antimalarial agent halofantrine. Br J Pharmacol 130:1967–1975

    Article  PubMed  CAS  Google Scholar 

  73. Warhurst DC, Craig JC, Adagu IS, Guy RK, Madrid PB, Fivelman QL (2007) Activity of piperaquine and other 4-aminoquinoline antiplasmodial drugs against chloroquine-sensitive and resistant blood-stages of Plasmodium falciparum. Role of beta-haematin inhibition and drug concentration in vacuolar water- and lipid-phases. Biochem Pharmacol 73:1910–1926

    Article  PubMed  CAS  Google Scholar 

  74. Tarning J, Lindegardh N, Annerberg A, Singtoroj T, Day NP, Ashton M, White NJ (2005) Pitfalls in estimating piperaquine elimination. Antimicrob Agents Chemother 49:5127–5128

    Article  PubMed  CAS  Google Scholar 

  75. Tarning J, Ashley EA, Lindegardh N, Stepniewska K, Phaiphun L, Day NP, McGready R, Ashton M, Nosten F, White NJ (2008) Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand. Antimicrob Agents Chemother 52:1052–1061

    Article  PubMed  CAS  Google Scholar 

  76. Briolant S, Henry M, Oeuvray C, Amalvict R, Baret E, Didillon E, Rogier C, Pradines B (2010) Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum. Antimicrob Agents Chemother 54:3537–3544

    Article  PubMed  Google Scholar 

  77. Muangnoicharoen S, Johnson DJ, Looareesuwan S, Krudsood S, Ward SA (2009) Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro. Antimicrob Agents Chemother 53:1362–1366

    Article  PubMed  CAS  Google Scholar 

  78. Ashley EA, Stepniewska K, Lindegardh N, McGready R, Annerberg A, Hutagalung R, Singtoroj T, Hla G, Brockman A, Proux S et al (2007) Pharmacokinetic study of artemether-lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria. Trop Med Int Health 12:201–208

    Article  PubMed  CAS  Google Scholar 

  79. van Vugt M, Wilairatana P, Gemperli B, Gathmann I, Phaipun L, Brockman A, Luxemburger C, White NJ, Nosten F, Looareesuwan S (1999) Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. Am J Trop Med Hyg 60:936–942

    PubMed  CAS  Google Scholar 

  80. Price RN, Uhlemann AC, van Vugt M, Brockman A, Hutagalung R, Nair S, Nash D, Singhasivanon P, Anderson TJ, Krishna S et al (2006) Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis 42:1570–1577

    Article  PubMed  CAS  Google Scholar 

  81. White NJ, van Vugt M, Ezzet F (1999) Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine. Clin Pharmacokinet 37:105–125

    Article  PubMed  CAS  Google Scholar 

  82. McGready R, Tan SO, Ashley EA, Pimanpanarak M, Viladpai-Nguen J, Phaiphun L, Wustefeld K, Barends M, Laochan N, Keereecharoen L et al (2008) A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated Plasmodium falciparum treatment in pregnancy. PLoS Med 5:e253

    Article  PubMed  Google Scholar 

  83. Anderson TJ, Nair S, Qin H, Singlam S, Brockman A, Paiphun L, Nosten F (2005) Are transporter genes other than the chloroquine resistance locus (pfcrt) and multidrug resistance gene (pfmdr) associated with antimalarial drug resistance? Antimicrob Agents Chemother 49:2180–2188

    Article  PubMed  CAS  Google Scholar 

  84. Johnson DJ, Fidock DA, Mungthin M, Lakshmanan V, Sidhu AB, Bray PG, Ward SA (2004) Evidence for a central role for PfCRT in conferring Plasmodium falciparum resistance to diverse antimalarial agents. Mol Cell 15:867–877

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuffield Department of Clinical Medicine, Centre for Tropical Medicine, Churchill Hospital, University of Oxford, Oxford, OX3 7LJ, UK

    Francois Nosten

  2. Shoklo Malaria Research Unit, 46, 68/30 Baan Tung Road, Mae Sot, Tak Province, 63110, Thailand

    Francois Nosten

  3. Mahidol University, Bangkok, Thailand

    Francois Nosten

  4. Centre for Public Health, Liverpool John Moores University, Liverpool, Henry Cotton Campus, 15–21 Webster Street, L3 2ET, Liverpool, UK

    Penelope A. Phillips-Howard

  5. Malaria Epidemiology Unit Child and Reproductive Health Group, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK

    Feiko O. ter Kuile

Authors
  1. Francois Nosten
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Penelope A. Phillips-Howard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Feiko O. ter Kuile
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francois Nosten .

Editor information

Editors and Affiliations

  1. Centre for Infection, Div. Cellular & Molecular Medicine, St. George's University of London, Cranmer Terrace, London, SW17 0RE, United Kingdom

    Henry M. Staines

  2. Medical School, Dept. Infectious Diseases, St. George´s Hospital, Cranmer Terrace, London, SW17 0RE, United Kingdom

    Sanjeev Krishna

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Basel AG

About this chapter

Cite this chapter

Nosten, F., Phillips-Howard, P.A., ter Kuile, F.O. (2011). Other 4-Methanolquinolines, Amyl Alcohols and Phentathrenes: Mefloquine, Lumefantrine and Halofantrine. In: Staines, H., Krishna, S. (eds) Treatment and Prevention of Malaria. Milestones in Drug Therapy. Springer, Basel. https://doi.org/10.1007/978-3-0346-0480-2_5

Download citation

Publish with us

Policies and ethics

Search

Navigation